Format

Send to

Choose Destination
Radiother Oncol. 2012 May;103(2):256-60. doi: 10.1016/j.radonc.2011.11.015. Epub 2011 Dec 24.

Urethra sparing - potential of combined Nickel-Titanium stent and intensity modulated radiation therapy in prostate cancer.

Author information

1
Department of Medical Physics, Oncology, Aalborg Sygehus, Aarhus University Hospital, Denmark. jabot@rn.dk

Abstract

BACKGROUND AND PURPOSE:

To investigate a novel method for sparing urethra in external beam radiotherapy of prostate cancer and to evaluate the efficacy of such a treatment in terms of tumour control using a mathematical model.

MATERIALS AND METHODS:

This theoretical study includes 20 patients previously treated for prostate cancer using external beam radiotherapy. All patients had a Nickel-Titanium (Ni-Ti) stent inserted into the prostate part of urethra. The stent has been used during the treatment course as an internal marker for patient positioning prior to treatment. In this study the stent is used for delineating urethra while intensity modulated radiotherapy was used for lowering dose to urethra. Evaluation of the dose plans were performed using a tumour control probability model based on the concept of uniform equivalent dose.

RESULTS:

The feasibility of the urethra dose reduction method is validated and a reduction of about 17% is shown to be possible. Calculations suggest a nearly preserved tumour control probability.

CONCLUSIONS:

A new concept for urethra dose reduction is presented. The method relies on the use of a Ni-Ti stent as a fiducial marker combined with intensity modulated radiotherapy. Theoretical calculations suggest preserved tumour control.

PMID:
22197354
DOI:
10.1016/j.radonc.2011.11.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center